Striving for Success
Capabilities
Pharmaron strives to be our client’s R&D service provider and their partner. We thrive on seeing our partners grow—especially when we can be there every step of the way.
On June 6, Goldfinch announced the start of its Phase l clinical trial for GFB-887, a small molecule TRPC5 inhibitor to treat kidney diseases. Since Goldfinch’s inception in December 2016, Pharmaron has provided services in medicinal chemistry, DMPK, in vitro biology, and process chemistry. For their clinical compound GFB-887, Pharmaron’s teams supported API manufacturing.
Written with permission by Goldfinch
Learn more about our small molecule services
